Clinic
Baptist Healthcare System INC.
Baptist Healthcare System INC. was paid $62.41M by Medicaid between Jan 2018 and Dec 2024, across 351 billing codes. Its largest line is 99284, emergency room visit (serious) — 10% of everything it billed.
33Billing provider infoBAPTIST HEALTHCARE SYSTEM INC.
LOUISVILLE, KY 40207
LOUISVILLE, KY 40207
33aNPI1265539498assigned 09/20/2006
33bProvider typeRehabilitation Clinic/Center
28Total paid$62.41M
24GClaims1,172,497
24DCodes billed351
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rehabilitation Clinic/Center providers in Kentucky
Rank by total paid#2 of 29
Median peer was paid$202K
This provider vs. median308×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official CARRICO, RICHARD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 114,002 | $5.11M | |
| 2019 | 125,974 | $5.74M | |
| 2020 | 128,768 | $5.54M | |
| 2021 | 170,748 | $8.63M | |
| 2022 | 188,196 | $10.06M | |
| 2023 | 239,333 | $13.88M | |
| 2024incomplete | 205,476 | $13.46M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10% | 26,309 | 21,608 | $6.48M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.7% | 31,705 | 27,520 | $5.41M |
| G0378 | Hospital observation service, per hour | 6.8% | 9,377 | 7,596 | $4.22M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.1% | 9,469 | 8,224 | $3.81M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.6% | 9,461 | 6,649 | $2.86M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 4.3% | 6,449 | 5,679 | $2.69M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 2.8% | 4,678 | 2,061 | $1.77M |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 2.5% | 1,296 | 1,077 | $1.59M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.3% | 8,256 | 6,410 | $1.41M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.2% | 3,399 | 2,753 | $1.40M |
| C1776 | Joint device (implantable) | 2.2% | 372 | 297 | $1.35M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.1% | 3,728 | 3,214 | $1.32M |
339 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | 1.6% | 11,307 | $991K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.6% | 23,036 | $990K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 9,901 | $907K |
| 93017 | 1.4% | 3,514 | $901K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.3% | 3,471 | $814K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.2% | 2,362 | $740K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 32,298 | $697K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 17,661 | $696K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.1% | 2,848 | $692K |
| 59025 | Fetal non-stress test | 1.1% | 7,455 | $679K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 25,143 | $675K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 10,346 | $602K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 4,942 | $591K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 12,536 | $547K |
| 80053 | Comprehensive metabolic panel | <1% | 69,891 | $542K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,607 | $536K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,242 | $520K |
| 96376 | <1% | 8,977 | $487K | |
| 71250 | <1% | 2,752 | $416K | |
| 71045 | Radiologic examination, chest; single view | <1% | 12,243 | $342K |
| 93458 | <1% | 276 | $340K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 68,974 | $328K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 59,723 | $314K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,950 | $312K |
| 93971 | <1% | 1,750 | $296K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,278 | $294K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 3,040 | $293K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,106 | $288K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 8,159 | $286K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 10,246 | $279K |
| 93976 | <1% | 2,588 | $272K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 2,431 | $255K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,385 | $254K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 11,355 | $238K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 836 | $237K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,699 | $231K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 5,868 | $226K |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 2,124 | $223K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,724 | $211K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,285 | $206K |
| 72110 | <1% | 1,999 | $202K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,745 | $185K |
| C1769 | Guide wire | <1% | 1,862 | $183K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,537 | $181K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,331 | $174K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 2,280 | $170K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 313 | $168K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 17,376 | $165K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 454 | $154K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 3,746 | $154K |
| 43775 | <1% | 55 | $152K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 2,993 | $152K |
| 83880 | <1% | 5,627 | $151K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 3,773 | $151K |
| 84484 | <1% | 17,770 | $150K | |
| J3490 | Unclassified drugs | <1% | 1,566 | $144K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 19,989 | $138K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 262 | $136K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 321 | $135K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 467 | $129K |
| 70496 | <1% | 424 | $126K | |
| 73560 | <1% | 2,103 | $126K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,597 | $123K |
| 73630 | <1% | 1,504 | $118K | |
| 76642 | <1% | 1,186 | $113K | |
| 73030 | <1% | 1,788 | $112K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,820 | $110K |
| 97161 | <1% | 3,092 | $103K | |
| 93970 | <1% | 441 | $98K | |
| 74018 | <1% | 1,759 | $96K | |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 933 | $96K |
| 88307 | <1% | 1,478 | $93K | |
| 73610 | <1% | 1,132 | $89K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 951 | $84K |
| J2704 | Injection, propofol, 10 mg | <1% | 18,172 | $80K |
| 76536 | <1% | 869 | $80K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,409 | $79K |
| 47563 | <1% | 69 | $78K | |
| 97162 | <1% | 3,218 | $77K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,337 | $77K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,708 | $76K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 9,904 | $76K |
| 88304 | <1% | 2,942 | $75K | |
| 97113 | <1% | 893 | $75K | |
| 85027 | <1% | 14,777 | $74K | |
| 76830 | Ultrasound, transvaginal | <1% | 867 | $72K |
| 84703 | <1% | 13,524 | $71K | |
| 83690 | <1% | 15,017 | $69K | |
| 0002A | <1% | 2,280 | $65K | |
| 73130 | <1% | 755 | $64K | |
| 0001A | <1% | 2,556 | $63K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,616 | $62K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 842 | $62K |
| 80061 | Lipid panel | <1% | 6,095 | $61K |
| 70498 | <1% | 268 | $61K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,527 | $58K |
| 72141 | <1% | 197 | $56K | |
| 19318 | <1% | 13 | $55K | |
| 82948 | <1% | 7,254 | $54K | |
| 84145 | <1% | 2,851 | $53K | |
| 82962 | <1% | 12,600 | $52K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 106 | $51K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 495 | $50K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 446 | $50K |
| 82077 | <1% | 3,921 | $50K | |
| 93325 | <1% | 612 | $49K | |
| 84112 | <1% | 654 | $49K | |
| 73502 | <1% | 868 | $46K | |
| 83735 | <1% | 9,360 | $45K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,885 | $45K |
| 27447 | <1% | 51 | $44K | |
| 77066 | Tomosynthesis, mammo | <1% | 507 | $43K |
| 72131 | <1% | 129 | $43K | |
| 95806 | <1% | 306 | $43K | |
| 74183 | <1% | 145 | $42K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 13,688 | $42K |
| 81001 | <1% | 17,071 | $42K | |
| 83605 | <1% | 5,151 | $41K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,337 | $40K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,895 | $40K |
| 88342 | <1% | 1,221 | $40K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,330 | $39K |
| 82607 | <1% | 3,595 | $39K | |
| 95886 | <1% | 159 | $39K | |
| 87040 | <1% | 5,255 | $38K | |
| 58661 | <1% | 55 | $37K | |
| 85610 | <1% | 11,198 | $37K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 15,686 | $36K |
| 82728 | <1% | 3,713 | $36K | |
| 76820 | <1% | 687 | $35K | |
| 70491 | <1% | 152 | $35K | |
| 96367 | <1% | 395 | $34K | |
| 94664 | <1% | 1,220 | $34K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,039 | $34K |
| 88341 | <1% | 235 | $34K | |
| 72100 | <1% | 395 | $33K | |
| 86850 | <1% | 4,036 | $33K | |
| 81025 | <1% | 6,232 | $32K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 147 | $32K |
| 76942 | <1% | 504 | $31K | |
| 82746 | <1% | 2,658 | $31K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,436 | $31K |
| 84702 | <1% | 3,084 | $31K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,730 | $28K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 878 | $26K |
| 0100U | <1% | 334 | $26K | |
| 73562 | <1% | 250 | $26K | |
| 85379 | <1% | 3,698 | $26K | |
| 73110 | <1% | 256 | $25K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,576 | $24K |
| 81003 | <1% | 11,646 | $22K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,536 | $22K |
| 80050 | General health panel | <1% | 628 | $22K |
| 72050 | <1% | 300 | $22K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 88 | $20K |
| 84439 | <1% | 3,105 | $20K | |
| 87070 | <1% | 3,186 | $19K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 73 | $19K |
| 76775 | <1% | 112 | $19K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 420 | $18K |
| 84425 | <1% | 1,029 | $18K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 218 | $18K |
| 64447 | <1% | 33 | $18K | |
| 77049 | <1% | 53 | $18K | |
| 70486 | <1% | 63 | $18K | |
| 87081 | <1% | 2,859 | $17K | |
| 85730 | <1% | 3,879 | $17K | |
| 83921 | <1% | 957 | $16K | |
| 77080 | <1% | 356 | $16K | |
| 83540 | <1% | 3,064 | $15K | |
| 99152 | <1% | 381 | $15K | |
| 84466 | <1% | 1,665 | $15K | |
| 84100 | <1% | 1,626 | $15K | |
| 90715 | <1% | 512 | $15K | |
| 87186 | <1% | 2,115 | $14K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 13,053 | $13K |
| 58563 | <1% | 12 | $13K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 2,283 | $12K |
| 0004A | <1% | 502 | $12K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,413 | $12K |
| 58558 | <1% | 12 | $11K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 26,715 | $11K |
| 94761 | <1% | 1,046 | $11K | |
| 86900 | <1% | 4,251 | $10K | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,669 | $10K |
| 86901 | <1% | 4,165 | $10K | |
| 84134 | <1% | 810 | $10K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 892 | $10K |
| 86140 | <1% | 2,619 | $10K | |
| 73590 | <1% | 112 | $10K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 2,420 | $9K |
| 36416 | <1% | 4,241 | $9K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 433 | $9K |
| 64415 | <1% | 51 | $9K | |
| 82803 | <1% | 473 | $9K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 657 | $8K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,558 | $8K |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 1,504 | $8K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 658 | $8K |
| 93356 | <1% | 319 | $8K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 10,392 | $8K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,077 | $8K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 623 | $8K |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 1,736 | $8K |
| 82550 | <1% | 1,575 | $8K | |
| 87205 | <1% | 2,483 | $8K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,337 | $8K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,431 | $8K |
| 87634 | <1% | 107 | $7K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,155 | $7K |
| 73221 | <1% | 25 | $7K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 329 | $7K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,650 | $7K |
| 72072 | <1% | 88 | $7K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,306 | $7K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,256 | $6K |
| 71271 | <1% | 97 | $6K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 984 | $6K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,166 | $6K |
| 73070 | <1% | 77 | $6K | |
| 80074 | <1% | 139 | $5K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 919 | $5K |
| 82570 | <1% | 1,158 | $5K | |
| 71101 | <1% | 92 | $5K | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 1,300 | $5K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,584 | $5K |
| 85014 | <1% | 1,655 | $5K | |
| 85652 | <1% | 2,486 | $5K | |
| 76825 | <1% | 39 | $5K | |
| 77065 | Tomosynthesis, mammo | <1% | 78 | $5K |
| 87077 | <1% | 683 | $5K | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 2,913 | $5K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,525 | $4K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 19 | $4K |
| 93922 | <1% | 50 | $4K | |
| 87147 | <1% | 622 | $4K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 10,225 | $4K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,684 | $4K |
| 84156 | <1% | 926 | $4K | |
| 78226 | <1% | 16 | $4K | |
| 87507 | <1% | 16 | $4K | |
| 80143 | <1% | 226 | $4K | |
| 74300 | <1% | 46 | $3K | |
| 72040 | <1% | 39 | $3K | |
| 87075 | <1% | 392 | $3K | |
| 88312 | <1% | 278 | $3K | |
| 87581 | <1% | 172 | $3K | |
| 87486 | <1% | 175 | $3K | |
| 76818 | <1% | 27 | $3K | |
| 87210 | <1% | 786 | $3K | |
| J0735 | Injection, clonidine hydrochloride, 1 mg | <1% | 231 | $3K |
| 80179 | <1% | 193 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,910 | $3K |
| 85018 | <1% | 1,603 | $3K | |
| 0054A | <1% | 106 | $2K | |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | <1% | 653 | $2K |
| 86803 | <1% | 223 | $2K | |
| 93880 | <1% | 20 | $2K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 317 | $2K |
| 83013 | <1% | 36 | $2K | |
| 94726 | <1% | 41 | $2K | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 295 | $2K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,114 | $2K |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,224 | $2K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,748 | $2K |
| 0399T | <1% | 61 | $2K | |
| 0011A | <1% | 79 | $2K | |
| 0012A | <1% | 69 | $2K | |
| C1726 | Catheter, balloon dilatation, non-vascular | <1% | 17 | $2K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 97 | $2K |
| 82784 | <1% | 93 | $1K | |
| 84132 | <1% | 420 | $1K | |
| 94060 | <1% | 12 | $1K | |
| 76827 | <1% | 40 | $1K | |
| C2617 | Stent, non-coronary, temporary, without delivery system | <1% | 15 | $1K |
| 83970 | <1% | 39 | $1K | |
| 93246 | <1% | 15 | $1K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 404 | $1K |
| 87015 | <1% | 225 | $1K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 294 | $1K |
| 88302 | <1% | 70 | $998.28 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 257 | $947.48 |
| 0124A | <1% | 36 | $915.20 | |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | <1% | 68 | $908.60 |
| 76801 | <1% | 21 | $906.69 | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 28 | $861.17 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 469 | $856.98 |
| 97116 | <1% | 161 | $841.68 | |
| 84550 | <1% | 240 | $828.18 | |
| 87631 | <1% | 19 | $815.43 | |
| 84436 | <1% | 134 | $786.28 | |
| 82378 | <1% | 64 | $785.44 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 17 | $772.20 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 94 | $763.15 |
| 83615 | <1% | 179 | $677.45 | |
| 36600 | <1% | 36 | $639.18 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 211 | $637.73 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,274 | $632.21 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 74 | $630.39 |
| 97012 | <1% | 76 | $552.49 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 391 | $516.17 |
| 81002 | <1% | 420 | $506.11 | |
| 84479 | <1% | 75 | $479.30 | |
| 97165 | <1% | 16 | $467.97 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 265 | $467.45 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 539 | $464.22 |
| 97166 | <1% | 12 | $404.05 | |
| C1758 | Catheter, ureteral | <1% | 29 | $367.86 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 553 | $356.00 |
| 99153 | Mod sedat endo service >5yrs | <1% | 13 | $344.37 |
| 0003A | <1% | 24 | $333.68 | |
| 87220 | <1% | 126 | $303.35 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 70 | $293.16 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 236 | $289.20 |
| C1755 | Catheter, intraspinal | <1% | 74 | $256.62 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 42 | $243.68 |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 13 | $236.90 |
| 86780 | <1% | 29 | $225.08 | |
| 84446 | <1% | 18 | $184.61 | |
| 84597 | <1% | 18 | $181.05 | |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 20 | $176.82 |
| Q9961 | High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml | <1% | 40 | $176.67 |
| 86308 | <1% | 42 | $176.12 | |
| 80306 | <1% | 12 | $165.74 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 92 | $162.49 |
| 84630 | <1% | 19 | $150.27 | |
| 84590 | <1% | 18 | $149.36 | |
| 82010 | <1% | 17 | $147.06 | |
| G0008 | Administration of influenza virus vaccine | <1% | 16 | $109.28 |
| 82731 | <1% | 14 | $100.93 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 16 | $93.21 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 44 | $87.65 |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 20 | $75.60 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 90 | $74.82 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 64 | $74.74 |
| 86592 | <1% | 19 | $72.39 | |
| 90686 | <1% | 16 | $55.11 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 36 | $19.54 |
| 99499 | 0% | 38 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCARRICO, RICHARD (CHIEF FINANCIAL OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.